Technical Analysis for SCPS - Scopus BioPharma Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.0500 | -1.96% | -0.0010 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.96% | |
| Narrow Range Bar | Range Contraction | -1.96% | |
| Stochastic Reached Oversold | Weakness | -1.96% | |
| Inside Day | Range Contraction | -1.96% | |
| Wide Bands | Range Expansion | -1.96% | |
| Oversold Stochastic | Weakness | -1.96% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| Down 1% | 1 day ago |
| Non-ADX 1,2,3,4 Bearish Retracement Entry | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
| Possible Inside Day | 2 days ago |
Get this analysis on your stocks daily!
Scopus BioPharma Inc. Description
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancers Gene Therapy Serious Diseases Mri Nitric Oxide
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.1682 |
| 52 Week Low | 0.04 |
| Average Volume | 15,148 |
| 200-Day Moving Average | 0.0000 |
| 50-Day Moving Average | 0.0632 |
| 20-Day Moving Average | 0.0614 |
| 10-Day Moving Average | 0.0606 |
| Average True Range | 0.0179 |
| RSI (14) | 45.36 |
| ADX | 28.79 |
| +DI | 29.9800 |
| -DI | 13.9078 |
| Chandelier Exit (Long, 3 ATRs) | 0.0513 |
| Chandelier Exit (Short, 3 ATRs) | 0.0967 |
| Upper Bollinger Bands | 0.0812 |
| Lower Bollinger Band | 0.0416 |
| Percent B (%b) | 0.21 |
| BandWidth | 64.4951 |
| MACD Line | -0.0027 |
| MACD Signal Line | -0.0013 |
| MACD Histogram | -0.0013 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.0500 | ||||
| Resistance 3 (R3) | 0.0500 | 0.0500 | 0.0500 | ||
| Resistance 2 (R2) | 0.0500 | 0.0500 | 0.0500 | 0.0500 | |
| Resistance 1 (R1) | 0.0500 | 0.0500 | 0.0500 | 0.0500 | 0.0500 |
| Pivot Point | 0.0500 | 0.0500 | 0.0500 | 0.0500 | 0.0500 |
| Support 1 (S1) | 0.0500 | 0.0500 | 0.0500 | 0.0500 | 0.0500 |
| Support 2 (S2) | 0.0500 | 0.0500 | 0.0500 | 0.0500 | |
| Support 3 (S3) | 0.0500 | 0.0500 | 0.0500 | ||
| Support 4 (S4) | 0.0500 |
